Suchergebnisse - "Sala, Luca"

PubPharm (4)

1

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

enthalten in: Cancer immunology, immunotherapy : CII | 2020

von Cortellini, A. | Tiseo, M. | Banna, G. | +67

2

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

enthalten in: Clinical lung cancer | 2020

von Cortellini, A. | Friedlaender, A. | Banna, G. | +68

3

Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab

enthalten in: Immunotherapy | 2020

von Alberti, A. | Mancin, M. | Cortinovis, D. | +2

4

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC) : An Italian, Multicenter, Retrospective Study

enthalten in: Clinical lung cancer | 2020

von Luciani, A. | Marra, A. | Toschi, L. | +19

1
[1]